Dr Reddy’s launches NIVORZ, a biosimilar to nivolumab, for 12 cancer indications after a 288-patient clinical programme, expanding its immuno-oncology portfolio.
Dr Reddy’s launches NIVORZ, a biosimilar to nivolumab, for 12 cancer indications after a 288-patient clinical programme, expanding its immuno-oncology portfolio.